Identification of Novel Loci Affecting Circulating Chromogranins and Related Peptides

Beben Benyamin,Adam X. Maihofer,Andrew J. Schork,Bruce A. Hamilton,Fangwen Rao,Geert W. Schmid-Schonbein,Kuixing Zhang,Manjula Mahata,Mats Stridsberg,Nicholas J. Schork,Nilima Biswas,Vivian Y. Hook,Zhiyun Wei,Grant W. Montgomery,Nicholas G. Martin,Caroline M. Nievergelt,John B. Whitfield,Daniel T. O'Connor
DOI: https://doi.org/10.1093/hmg/ddw380
IF: 5.1214
2017-01-01
Human Molecular Genetics
Abstract:Chromogranins are pro-hormone secretory proteins released from neuroendocrine cells, with effects on control of blood pressure. We conducted a genome-wide association study for plasma catestatin, the catecholamine release inhibitory peptide derived from chromogranin A (CHGA), and other CHGA- or chromogranin B (CHGB)-related peptides, in 545US and 1252 Australian subjects. This identified loci on chromosomes 4q35 and 5q34 affecting catestatin concentration (P = 3.40 x 10(-30) for rs4253311 and 1.85 x 10(-19) for rs2731672, respectively). Genes in these regions include the proteolytic enzymes kallikrein (KLKB1) and Factor XII (F12). In chromaffin cells, CHGA and KLKB1 proteins co-localized in catecholamine storage granules. In vitro, kallikrein cleaved recombinant human CHGA to catestatin, verified by mass spectrometry. The peptide identified from this digestion (CHGA360-373) selectively inhibited nicotinic cholinergic stimulated catecholamine release from chromaffin cells. A proteolytic cascade involving kallikrein and Factor XII cleaves chromogranins to active compounds both in vivo and in vitro.
What problem does this paper attempt to address?